A Randomized, Open-Label Study to Evaluate the Pharmacokinetics and Safety of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc; BIIB031) Manufactured at 15K Scale and at Different Vial Strengths in Previously Treated Subjects With Severe Hemophilia A

Trial Profile

A Randomized, Open-Label Study to Evaluate the Pharmacokinetics and Safety of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc; BIIB031) Manufactured at 15K Scale and at Different Vial Strengths in Previously Treated Subjects With Severe Hemophilia A

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 10 Jun 2017

At a glance

  • Drugs Efmoroctocog alfa (Primary)
  • Indications Haemophilia A
  • Focus Pharmacokinetics; Registrational
  • Acronyms Elevate
  • Sponsors Biogen; Bioverativ
  • Most Recent Events

    • 02 Jun 2017 Planned End Date changed from 1 Apr 2017 to 1 Jun 2017.
    • 15 Sep 2016 Status changed from recruiting to active, no longer recruiting.
    • 15 Jan 2016 Planned End Date changed from 1 Dec 2016 to 1 Apr 2017 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top